Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both

James, N.D., Pirrie, S.J., Pope, A.M. et al. (19 more authors) (2016) Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both. JAMA Oncology, 2 (4). p. 493. ISSN 2374-2437

Metadata

Authors/Creators:
  • James, N.D.
  • Pirrie, S.J.
  • Pope, A.M.
  • Barton, D.
  • Andronis, L.
  • Goranitis, I.
  • Collins, S
  • Daunton, A.
  • McLaren, D.
  • O’Sullivan, J.
  • Parker, C.
  • Porfiri, E.
  • Staffurth, J.
  • Stanley, A.
  • Wylie, J.
  • Beesley, S.
  • Birtle, A.
  • Brown, J.
  • Chakraborti, P.
  • Hussain, S.
  • Russell, M.
  • Billingham, L.J.
Copyright, Publisher and Additional Information: © 2016 American Medical Association. This is an author produced version of a paper subsequently published in JAMA Oncology. Uploaded in accordance with the publisher's self-archiving policy.
Dates:
  • Published: 1 April 2016
  • Accepted: 6 November 2015
  • Published (online): 21 January 2016
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Medicine (Sheffield) > Division of Genomic Medicine (Sheffield) > Department of Oncology (Sheffield)
The University of Sheffield > Sheffield Teaching Hospitals
Depositing User: Symplectic Sheffield
Date Deposited: 13 Jul 2016 15:53
Last Modified: 14 Apr 2017 03:38
Published Version: http://dx.doi.org/10.1001/jamaoncol.2015.5570
Status: Published
Publisher: American Medical Association
Refereed: Yes
Identification Number: https://doi.org/10.1001/jamaoncol.2015.5570

Share / Export

Statistics